Materials
Session I: Welcome & Introductory Remarks
Introductions and Welcome
Judith Ertle, Boehringer Ingelheim
Veronica Miller, Forum for Collaborative Research
Arun Sanyal, Virginia Commonwealth University
Session II: Steatotic Liver Diseases: Review of New Nomenclature from Multi-Stakeholders Perspectives
Overview of Nomenclature Consensus, Challenges, and the Future
Arun Sanyal, Virginia Commonwealth University
Meena Bansal, Mount Sinai Hospital, NY
Sven Francque*, University of Antwerp, Belgium
George Makar*, FDA
Joachim Musaus, EMA
Don Chalfin, Patient
Henry Chang*, Fatty Liver Foundation
Michelle Long, Novo Nordisk
Judith Ertle, Boehringer Ingelheim
Session III: Advances in Digital Pathology & AI/ML for MASH
The Role of AI/ML in MASH: Digital Pathology
Dean Tai, HistoIndex
The Role of AI/ML in MASH: Digital Pathology
Janani Iyer & Katy Wack, PathAI
The Role of AI/ML in MASH: Digital Pathology
Mathieu Petitjean, PharmaNest
The Role of AI/ML in MASH: Digital Pathology
Cindy Serdjebi, BioCellvia
Session IV: Moving Forward with NITs
Brief Overview of Liver Forum Work in NITs
Veronica Miller, Forum for Collaborative Research
FDA NIT Workshop: Open Invitation
Abbas Bandukwala*, US Food and Drug Administration
Proposal to the Liver Forum: 1) Consensus on non-invasive marker data to collect and report 2) Designing NIT-based trials
Quentin Anstee*, Newcastle University
Session V: Stretch Exercise: Pragmatic Benefit-Risk Assessment for Diagnostics
A New Look at Benefit-Risk in Diagnostics
Scott Evans, George Washington University
Session VI: Working Group Updates and Proposals
MASH (NASH) Placebo Arm Database
Michael Cooreman, Inventiva Pharma
Combination Therapy
Michelle Long, Novo Nordisk
Pooling of Endpoints Across Trials
Michelle Long, Novo Nordisk
Discussant
Laurent Castera, Université Paris Cite Hôpital Beaujon
New Working Group: Radiology Liver Diseases (RLD) Program
Michael Middleton, UC San Diego
New Working Group: Intersection of Steatotic Liver Disease (SLD) and Alcohol Liver Disease (ALD)- Met-ALD
Nikhil Vergis, GlaxoSmithKline
Discussant
Donna Cryer, Global Liver Institute
Roberto Calle*, Regeneron
*Remote participation
